PMID- 22074997
OWN - NLM
STAT- MEDLINE
DCOM- 20120518
LR  - 20211021
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Print)
IS  - 0198-8859 (Linking)
VI  - 73
IP  - 1
DP  - 2012 Jan
TI  - Identification of HLA-A24-restricted CD8(+) cytotoxic T-cell epitopes derived 
      from mammaglobin-A, a human breast cancer-associated antigen.
PG  - 11-6
LID - 10.1016/j.humimm.2011.10.017 [doi]
AB  - Human breast cancer-associated antigen, mammaglobin-A (Mam-A), potentially offers 
      a novel therapeutic target as a breast cancer vaccine. In this study, we define 
      the CD8(+) cytotoxic T lymphocyte (CTL) response to Mam-A-derived candidate 
      epitopes presented in the context of HLA-A24 (A*2402). HLA-A24 has a frequency of 
      72% in Japanese, 27% in Asian Indian, and 18% in Caucasian populations. Using a 
      human leukocyte antigen (HLA)-binding prediction algorithm we identified 7 
      HLA-A24-restricted Mam-A-derived candidate epitopes (MAA24.1-7). Membrane 
      stabilization studies with TAP-deficient T2 cells transfected with HLA-A2402 
      (T2.A24) indicated that MAA24.2 (CYAGSGCPL) and MAA24.4 (ETLSNVEVF) have the 
      highest HLA-A24 binding affinity. Further, 2 CD8(+) CTL cell lines generated in 
      vitro against T2.A24 cells individually loaded with Mam-A-derived candidate 
      epitopes demonstrated significant cytotoxic activity against MAA24.2 and MAA24.4. 
      In addition, the same CD8(+) CTL lines lysed the HLA-A24(+)/Mam-A(+) stable 
      transfected human breast cancer cell lines AU565 and MDA-MB-361. However, these 
      CTLs had no cytotoxicity against HLA-A24(-)/Mam-A(+) and HLA-A24(+)/Mam-A(-) 
      breast cancer cell lines. In summary, our results define HLA-A24-restricted, 
      Mam-A-derived, CD8(+) CTL epitopes that can potentially be employed for 
      Mam-A-based breast cancer vaccine therapy to breast cancer patients with HLA-A24 
      phenotype.
CI  - Copyright (c) 2012 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Tiriveedhi, Venkataswarup
AU  - Tiriveedhi V
AD  - Department of Surgery, Washington University School of Medicine, Saint Louis, 
      Missouri 63110, USA.
FAU - Sarma, Nayan J
AU  - Sarma NJ
FAU - Subramanian, Vijay
AU  - Subramanian V
FAU - Fleming, Timothy P
AU  - Fleming TP
FAU - Gillanders, William E
AU  - Gillanders WE
FAU - Mohanakumar, Thallachallour
AU  - Mohanakumar T
LA  - eng
GR  - P30 CA091842/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20111023
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (CD8 Antigens)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (HLA-A24 Antigen)
RN  - 0 (Mammaglobin A)
SB  - IM
MH  - Amino Acid Sequence
MH  - Binding, Competitive/immunology
MH  - Breast Neoplasms/genetics/*immunology/pathology
MH  - CD8 Antigens/immunology/metabolism
MH  - Cancer Vaccines/genetics/immunology/metabolism
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Cytotoxicity, Immunologic/immunology
MH  - Epitope Mapping
MH  - Epitopes, T-Lymphocyte/genetics/*immunology/metabolism
MH  - Female
MH  - HLA-A24 Antigen/genetics/*immunology/metabolism
MH  - Humans
MH  - Mammaglobin A/genetics/*immunology
MH  - Protein Binding/immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
MH  - Transfection
PMC - PMC3674634
MID - NIHMS464460
EDAT- 2011/11/15 06:00
MHDA- 2012/05/19 06:00
PMCR- 2013/06/06
CRDT- 2011/11/15 06:00
PHST- 2011/07/29 00:00 [received]
PHST- 2011/07/29 00:00 [revised]
PHST- 2011/10/12 00:00 [accepted]
PHST- 2011/11/15 06:00 [entrez]
PHST- 2011/11/15 06:00 [pubmed]
PHST- 2012/05/19 06:00 [medline]
PHST- 2013/06/06 00:00 [pmc-release]
AID - S0198-8859(11)00563-5 [pii]
AID - 10.1016/j.humimm.2011.10.017 [doi]
PST - ppublish
SO  - Hum Immunol. 2012 Jan;73(1):11-6. doi: 10.1016/j.humimm.2011.10.017. Epub 2011 
      Oct 23.